Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CLK2 | P49760 | 6/20 | 0.54 |
| ▸ | CLK3 | P49761 | 6/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.54 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCND3 | P30281 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538139 | 0.91 | ALDH1A1 (0.57) | KDM4ENPC1ALDH1A1PKMHPGD | |
| SCHEMBL3542692 | 0.86 | PDPK1 (0.56) | KDM4ENPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3538807 | 0.84 | ALDH1A1 (0.58) | ALDH1A1PKMCLK2CLK3DYRK1A | |
| SCHEMBL3531870 | 0.84 | PDPK1 (0.71) | CLK2CLK3DYRK1AMAP3K8PDPK1 | |
| SCHEMBL17555489 | 0.83 | CLK2 (0.57) | KDM4ENPC1ALDH1A1PKMHPGD | |
| SCHEMBL3536504 | 0.82 | FGFR1 (0.73) | CLK2CLK3DYRK1AMAP3K8PDPK1 | |
| SCHEMBL15306836 | 0.80 | CLK3 (0.71) | CLK2CLK3DYRK1AMAP3K8PDPK1 | |
| SCHEMBL5951667 | 0.80 | MAP3K8 (0.51) | CLK2DYRK1AMAP3K8PDPK1CHUK | |
| SCHEMBL3532319 | 0.79 | PDPK1 (0.51) | CLK2DYRK1AMAP3K8PDPK1CHUK | |
| SCHEMBL15306839 | 0.78 | WNT1 (0.70) | CLK2CLK3DYRK1AMAP3K8CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | KDM4E 2648/4885NPC1 1789/4885ALDH1A1 1562/4885 |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | KDM4E 1513/4885NPC1 891/4885ALDH1A1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.